Oral and Genital Lichen Planus: A Comprehensive Review of Co-Manifestation
Authors/Creators
- 1. International Journal of Medical Science and Advanced Clinical Research (IJMACR)
Description
Abstract
Lichen planus (LP) is a chronic immune-mediated inflammatory disease affecting skin, mucosa, nails, and hair. Oral lichen planus (OLP) affects 1–3% of adults aged 30–60 years and exhibits a female predominance. Genital lichen planus (GLP) often co-occurs with OLP but is underdiagnosed due to asymptomatic or subtle presentation. Studies indicate that 19–57% of OLP patients—with up to 92% asymptomatic genital involvement—have GLP. Erosive variants pose a 1–4% risk of malignant transformation. The disease is driven by CD8⁺ T-cell–mediated basal keratinocyte apoptosis, involving genetic predisposition (e.g., HLA‑DQB1*0201), infections (HCV, HPV), stress, and medications. Diagnosis requires thorough mucosal examination and histopathological confirmation. First-line management includes topical corticosteroids; systemic immunomodulators and emerging therapies such as JAK inhibitors are increasingly used. Multidisciplinary care with biannual-to-annual monitoring is essential given functional morbidity and cancer risk.
Files
KHAN.pdf
Files
(893.3 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:46742d929ec4dea62599de8516a2635a
|
893.3 kB | Preview Download |
Additional details
Software
- Repository URL
- https://ijmacr.com/issue/archive_issue/61
References
- 1. Webber J, et al. Update on lichen planus pathogenesis. J Clin Pathol. 2025;78(2):123–31. 2. Lodi G, et al. Oral lichen planus: epidemiology and clinical presentation. Clin Dermatol. 2021;39(5):512–8. 3. Lamey PJ, Lamb AB, et al. Oral lichen planus and malignant transformation risk: a multiyear study. J Oral Pathol Med. 1990;19(6):241–5. 4. Di Fede O, Belfiore P, Cabibi D, et al. Genital involvement in women with oral lichen planus. Acta Derm Venereol. 2006;86(5):433–8. 5. Clark C, Wojnarowska F, et al. Vulval lichen planus: prevalence in oral LP. Acta Derm Venereol. 2006;86(5):433–8. 6. González López MA, et al. Mucosal lichen planus: distribution and clinical features. Med Oral Patol Oral Cir Bucal. 2019;24(1):e1–10. 7. Al Maweri SA, et al. Prevalence of mucosal lesions in LP: A systematic review. Oral Dis. 2022;28(3):567–575. 8. Smith NN, et al. Epidemiology of generalized lichen planus: mucosal involvement. Dermatology. 2023;239(1):45–52. 9. Ng S, et al. Diagnostic criteria and management recommendations in oral LP. Oral Dis. 2023;29(1):33–47. 10. Li D, Li J, Li C, et al. Clinical patterns and complications of genital lichen planus. Int J Dermatol. 2024;63(4):481–9. 11. Setterfield JF, et al. Vulvovaginal-gingival syndrome: definition and outcomes. JAAD. 2006;55(1):98–113. 12. Shwetha V, Sujatha S, et al. Photodynamic therapy in treatment-resistant mucosal lichen planus. J Oral Maxillofac Pathol. 2023;27(3):111–7. 13. Patel DN, et al. Hydroxychloroquine in erosive oral lichen planus: a randomized trial. Oral Dis. 2020;26(4):1000–8. 14. Uzunçakmak TK, Karadağ AS, et al. Vulvovaginal-gingival syndrome case series and management. J Turk Acad Dermatol. 2020;14(1):23–25. 15. Olszewska M, et al. Autoantibodies and lichen planopilaris association. Acta Derm Venereol. 2016;96(1):92–6. 16. Kaufman R, et al. Cochrane review on OLP interventions. Cochrane Database Syst Rev. 2020;3:CD001168. 17. Frontiers editorial. Erosive lichen planus unmet needs. Front Med. 2024;11:1457667. 18. Salazar Riobóó A, Banks Simms AM. Calcitriol and tacrolimus in mucosal LP. Dermatol Ther. 2023;36(6):e15904. 19. Macken JH, et al. Systemic treatments for severe mucosal lichen planus. Acta Derm Venereol. 2024;104(3):dav169. 20. Chow MR, et al. Case reports: JAK inhibitors in refractory oral LP. SAGE Open Med Case Rep. 2023;11:2050313X231164216.